Ytibira Tablet
Marketer
Ytiliga Private Limited
Salt Composition
Abiraterone Acetate (250mg)
Overview Ytibira Tablet
Prostate cancer treatment often includes Ytibira tablets. A physician may prescribe this medication for other conditions as well, sometimes incorporating it into combination chemotherapy regimens. Ytibira should be taken with food to minimize side effects; taking it on an empty stomach is not recommended. Dosage and frequency are determined by your doctor based on your individual needs and may be adjusted over time. Strict adherence to your doctor's instructions is crucial, as incorrect usage or overdose can lead to serious adverse reactions. Therapeutic benefits may not be apparent for weeks or months; discontinue use only as directed by your physician. Common side effects include nausea, hypokalemia (low blood potassium), swelling, leukopenia (low white blood cell count), and tiredness. Report any concerning or severe side effects to your doctor, as management strategies exist. Less frequent, but potentially indicative of liver problems, are jaundice (yellowing of the skin), anorexia (loss of appetite), dyspnea (shortness of breath), dark urine, and vomiting. Your doctor may monitor liver function, blood pressure, and potassium levels. Prior to commencing treatment, inform your doctor of any pre-existing conditions such as hypertension (high blood pressure), cardiac issues, liver or kidney disease, or the use of any antimicrobial medications. Ytibira can interact with numerous other drugs; disclose all medications currently being taken. This medication is contraindicated during pregnancy and lactation due to potential harm to the developing fetus. Reliable contraception is essential for both partners throughout the treatment period. Regular blood glucose monitoring may also be required during therapy.
Uses of Ytibira Tablet
Malignancy of the prostate gland
Major Benefits of Ytibira Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. Ytibira Tablets should be taken on an empty stomach.
Common Side effects of Ytibira Tablet:
- Edema (swelling)
- Vomiting
- Decreased potassium level in blood
- Fatigue
- Anemia (low number of red blood cells)
- Urinary tract infection
- Diarrhea
- High blood pressure
- Cough
- Joint swelling
How to use Ytibira Tablet:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the Ytibira Tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication on an empty stomach.
How Ytibira Tablet works:
Ytibira tablets are an anti-cancer drug that suppresses prostate cancer growth by targeting male hormone production. The medication achieves this by blocking the activity of the CYP17 enzyme, a key player in androgen synthesis.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The interaction of Ytibira Tablet with alcohol is unknown; therefore, physician consultation is recommended.
PregnancyUNSAFE
The use of Ytibira Tablets is strongly contraindicated during pregnancy. Pregnant women should consult their physician, as research in both animal and human studies has revealed substantial adverse effects on fetal development.
Breast feedingUNSAFE
Lactation and Ytibira Tablet are incompatible. Evidence indicates potential infant toxicity from this medication.
DrivingSAFE
Driving ability is typically unaffected by Ytibira Tablet.
KidneyCAUTION
Patients with significant kidney impairment should exercise caution when using Ytibira Tablets. Dosage modification may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with liver impairment should exercise caution when using Ytibira Tablets; dosage modification may be necessary. Physician consultation is recommended.
What if you forget to take Ytibira Tablet :
Omit any missed Ytibira Tablet dose and resume your regular medication schedule. Avoid taking a double dose.
Facts to Know About Ytibira Tablet
| Label | Value |
|---|---|
| Chemical Type | Androstenedione derivative |
| Developing Habits | No. |
| Treatment Category | Cancer Therapeutics |



